New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
17:50 EDTARWR, ALNYArrowhead Research reiterates patent position
Arrowhead Research (ARWR) reaffirmed its belief that it has broad access to intellectual property required to develop ARC-520, its clinical candidate against chronic hepatitis B infection. Arrowhead does not believe there are additional unlicensed patents directed to RNAi therapeutics targeting the hepatitis B virus that affect its freedom to operate. The company signed a license agreement with Alnylam Pharmaceuticals (ALNY) in January 2012, giving it access to intellectual property that enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus. Arrowhead holds multiple levels of patent protection on ARC-520 including U.S. Patent Nos. 8,313,772 and 8,501,930 covering the Dynamic Polyconjugate delivery system, and U.S. Patent Application number 13/535,454 covering ARC-520ís siRNA component, which was recently allowed by the U.S. Patent and Trademark Office. Arrowhead and its legal advisors continually review the patent landscape to ensure freedom to operate and the company believes that development and commercialization of ARC-520 would not infringe patents governing RNAi therapeutics targeting the hepatitis B virus, including U.S. Patent No. 8,618,277 in the McSwiggen patent estate.
News For ARWR;ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
10:49 EDTARWRArrowhead strengthened position in RNAi with Novartis deal, says Piper Jaffray
After Arrowhead Research (ARWR) purchased Novartisí (NVS) RNAi R&D portfolio and associated assets for $35M in cash and stock, Piper Jaffray said it believes the deal further consolidates and strengthens Arrowhead's position in the RNAi space. The firm maintains its $12 price target and Overweight rating on Arrowhead shares.
08:01 EDTARWRArrowhead to host conference call
Subscribe for More Information
07:31 EDTARWR, ALNYArrowhead acquires Novartis' RNAi research and development portfolio
Subscribe for More Information
March 4, 2015
10:01 EDTALNYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:10 EDTALNYCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 4 at 8 am; not all company presentations may be webcasted. Webcast Link
05:37 EDTALNYAlnylam initiated with an Overweight at Barclays
Subscribe for More Information
February 27, 2015
09:58 EDTALNYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:59 EDTALNYAlnylam initiated with an Outperform at Cowen
Subscribe for More Information
February 23, 2015
07:33 EDTARWRArrowhead initiates dosing in phase 1 trial of ARC-AAT
Subscribe for More Information
07:22 EDTALNYSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use